請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27050
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李吉仁 | |
dc.contributor.author | Lin-Hung Wei | en |
dc.contributor.author | 魏凌鴻 | zh_TW |
dc.date.accessioned | 2021-06-12T17:54:29Z | - |
dc.date.available | 2008-02-18 | |
dc.date.copyright | 2008-02-18 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-02-04 | |
dc.identifier.citation | REFERENCES
Alain, J. G., & Mark, L. 2004. Risky Business. Scrip Magazine, September. Avidor, Y., Mabjeesh, N. J., & Matzkin, H. 2003. Biotechnology and drug discovery: from bench to bedside. Southern Medical Journal, 96(12), 1174-1186. Burstein, H. J. 2005. The distinctive nature of HER2-positive breast cancers. New England Journal of Medicine, 353(16), 1652-1654. Chanda, S. K., & Caldwell, J. S. 2003. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discovery Today, 8(4), 168-174. Cutler, D. M., 2007. The Demise of the Blockbuster? New England Journal of Medicine, 356(13), 1292-1293. Danzon, P. M., Nicholson, S. & Pereira, N. S. 2005. Productivity in pharmaceutical- biotechnology R&D: the role of experience and alliances. Journal of Health Economics, 24, 317–339. DiMasi, J. A. & Grabowski, H. G. 2007. Economics of New Oncology Drug Development. Journal of Clinical Oncology, 25(2), 209-216. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22(2), 151-185. Dervieux1, T & Bala, M. V. 2006. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics, 7(8), 1175-1184. Drews, J. 2000. Drug discovery: a historical perspective. Science, 287(5460), 1960-1964. Drews, J., & Ryser, S. 1997. The role of innovation in drug development. Natural Biotechnology, 15(13), 1318-1319. Erlich, H., Bonnet, J., Frueh, F. W., Bertrand, P., Schmitz, G., Salvatore, G., et al. 2003. Pharmacogenetics: from bench to bedside. Clinical Chemistry & Laboratory Medicine, 41(4), 610-614. Ernst, F. R., & Grizzle, A. J. 2001. Drug-related morbidity and mortality: updating the cost-of-illness model. Journal of the American Pharmacists Association (Wash), 41(2), 192-199. Evans, W. E., & Johnson, J. A. 2001. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annual Review of Genomics and Human Genetics, 2, 9-39. Evans, W. E., & McLeod, H. L. 2003. Pharmacogenomics--drug disposition, drug targets, and side effects. New England Journal of Medicine, 348(6), 538-549. Evans, W. E., & Relling, M. V. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286(5439), 487-491. Fleming, A. 1955. The story of penicillin. Bull Georgetown University Medical Center, 8(4), 128-132. Frueh, F. W., & Gurwitz, D. 2004. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics, 5(5), 571-579. Gardiner, S. J., & Begg, E. J. 2005. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics, 15(5), 365-369. Gilbert, J., Henske, P., & Singh, A. 2003. Rebuilding Big Pharma’s Business Model. IN VIVO, WINDHOVER INFORMATION INC., 21(10) Gillick, M. R. 2004. Medicare coverage for technological innovations--time for new criteria? New England Journal of Medicine, 350(21), 2199-2203. Hanahan, D., & Weinberg, R. A. 2000. The hallmarks of cancer. Cell, 100(1), 57-70. Hitt, M. A., Keats, B. W., & DeMaiie, S. M. 1998. Navigating in the new competitive landscape: Building strategic flexibility and competitive advantage in the 21st century. Academy of Management Executive, 12(4), 22-43. Hoag, H. 2004. Testing new ground. Nature 429, 682–683. Ito, R. K. & Demers, L. M. 2004. Pharmacogenomics and pharmacogenetics: future role of molecular diagnostics in the clinical diagnostic laboratory. Clinical Chemistry. 50, 1526–1527. Jerry, C. & Bill, S. 2006. Pharma’s next model. Pharmaceutical Executive, March. Jesse J. S., Tom W. H., Hans, G., Elisabeth G. E. de Vries, Willem J. J., Assendelft, J. K., & Henk-Jan, G. 2007. Translating Pharmacogenomics: Challenges on the Road to the Clinic. PLoS Medicine, 4 (8) 1317-24. Johnson, J. A., & Bootman, J. L. 1995. Drug-related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine, 155(18), 1949-1956. Kollek, R., van Aken, J., Feuerstein, G., & Schmedders, M. 2006. Pharmacogenetics, adverse drug reactions and public health. Community Genetics, 9(1), 50-54. Lazarou, J., Pomeranz, B. H., & Corey, P. N. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. The Journal of the American Medical Association, 279(15), 1200-1205. Leonard, T. & Schneider, J. 2004. Integrated sustainability in the pharmaceutical industry. International Journal for Sustainable Business, 11(5), 119-128. Liu, B., Li, S., & Hu, J. 2004. Technological advances in high-throughput screening. American Journal of Pharmacogenomics, 4(4), 263-276. McGuigan, F. E., Reid, D. M., & Ralston, S. H. 2000. Susceptibility to osteoporotic fracture is determined by allelic variation at the Sp1 site, rather than other polymorphic sites at the COL1A1 locus. Osteoporosis International, 11(4), 338-343. Nielsen, R., Hellmann, I., Hubisz, M., Bustamante, C., & Clark, A. G. 2007. Recent and ongoing selection in the human genome. Natural Reviews Genetics, 8(11), 857-868. O’Reilly, C. A. & Tushman, M. L. 2007. Ambidexterity as a dynamic capability: resolving the innovator’s Dilemma. Boston, MA: Harvard University working paper. Phillips, K. A., & Van Bebber, S. L. 2004. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics, 5(8), 1139-1149. Porter, M. E. 1996. What is Strategy? Harvard Business Review, November-December, 61-78. Reichert, J. M., & Valge-Archer, V. E. 2007. Development trends for monoclonal antibody cancer therapeutics. Natural Review Drug Discovery, 6(5), 349-356. Roses, A. 2000. Pharmacogenetics and future drug development and delivery. Lancet, 355, 1358-1361. Rothstein, M. A. 2005. Genetic exceptionalism and legislative pragmatism. Hastings Center Report, 35, 27–33. Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., Marth, G., et al. 2001. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature, 409(6822), 928-933. Shi, M. M. 2002. Diagnostics meets therapeutics: the impact of pharmacogenetics. Drug Discovery Today. 7(23),1161-1162 Teece, D. J. 2006. Explicating dynamic capabilities: The nature and microfoundations of (sustainable) enterprise performance. Haas School of Business Working Paper, Dec. 22. Trusheim, M. R., Berndt, E. R., & Douglas, F. L. 2007. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Natural Reviews Drug Discovery, 6(4), 287-293. Tushman, M. L. & O’Reilly, C. A. 1997. Winning through innovation: A practical guide to leading organizational change and renewal. Boston, MA: Harvard University Press. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDER). Guidance for Industry: Pharmacogenomic Data Submissions [online], <http://www.fda.gov/cder/guidance/6400fnl.pdf> (2005A). Guidance on voluntary genomic data submissions. US Food and Drug Administration, Drug-Diagnostic Co-Development Concept Paper [online], <http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf> (2005B). Concept paper on how drugs and diagnostics might be co-developed and regulated in the near future. Womack, C. 2004. In ‘Critical Path’ Update, Novartis Official Said Industry Should Share Biomarker Data. The Pharmacogenomics Reporter 12/9. Worthen, D. B. 2002. The pharmaceutical industry, 1952-2002. Journal of the American Pharmacists Association (Wash), 42(5), 683-686. Wright S. 1984. Evolution and the Genetics of Populations: Genetic and Biometric Foundations. Univ. of Chicago Press, Chicago, IL. Yan, L., & Beckman R. A. 2005. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques, 39(4), 565-568. Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W., & Chen, Y. Z. 2006. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacological Reviews, 58(2), 259-279. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27050 | - |
dc.description.abstract | 生物製藥產業在二十一世紀所面臨的一項最大挑戰將是發展藥物以提供臨床應用於特定族群病人。這些病人是依據不同的臨床分子生物指標進行分類,這種醫療模式我們稱之為「分層醫學」。這種從「明星藥」轉變成個人化醫療的趨勢,將大大改變未來藥物發展、行銷、以及處方的模式。顯然的,今日的大型製藥公司正面臨著全新的競爭實境,產業的景觀正逐漸轉變成傳統製藥公司高度不熟悉的情境。在這項探索性的研究裡,我們探討在逐漸分層的醫學發展下,它對製藥產業結構、獲利能力、競爭動態、及永續性的影響。我們預期,未來製藥產業的垂直專業化分工將成為趨勢,而目前的垂直整合製藥模式將逐漸式微,取而代之的將是各式不同的結盟及合作。我們設想在未來的製藥產業中,最大的參與者或許是知識管理公司,亦即疾病管理公司。 | zh_TW |
dc.description.abstract | One of the biggest challenges for the biopharmaceutical industry in the 21st century will be to develop and deliver drugs that matched with specific patient population characteristics using clinical biomarkers- which we call stratified medicine. This change from blockbuster medicine to personalized medicine will, to a large extent, influence the way that drugs are going to be developed, marketed and prescribed in the future. Apparently, Big Pharma today is facing new competitive realities. Their landscape is shifting in highly unfamiliar ways as traditional industry maps out. In this study, we review and discuss the economic implications of increasingly stratified medicines for industry structure, profitability, competitive dynamics and long-term sustainability. We envision vertical specialization will become the norm. The pharmaceutical industry will be vertically disintegrated by a wide variety of alliances and other collaborative enterprises. We wonder whether or not the biggest players in the pharmaceutical industry of the future would, in fact, be knowledge management companies, or perhaps disease management companies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T17:54:29Z (GMT). No. of bitstreams: 1 ntu-97-P93743020-1.pdf: 1766442 bytes, checksum: 158d325d551360ba48dc27eba1e21b38 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | Content
中文摘要…………………………………………………………………………………4 Abstract………………………………………………………………………………….5 Chapter 1 Introduction………………………………………………………………….6 1.1. Background and Significance………………………………………………...6 1.2. Research Questions and Objectives…………………………………..............7 1.3. Research Methodology and Limitations…………………………………….. 8 1.4. Thesis Roadmap………………………………………………………………8 Chapter 2 Literature Review on Biopharmaceutical Industry………………………..9 2.1. Drug Discovery: A Historical Perspective……………………………………9 2.2. Drug Discovery in the Postgenomic Era…………………………………….11 2.3. Industry Overview and Outlook……………………………………………..12 2.4. Key Elements of the Pharmaceutical Value Chain………………………….20 2.5. Pharmacogenomic Applications in Research, Development, and Medicine..24 2.6. Strategy in the New Competitive Landscape………………………………..27 Chapter 3 Regulatory Overview……………………………………………………….30 3.1. Current Regulatory Process for Drug Development………………………...30 3.2. FDA Pharmacogenomics Regulation Proposal……………………………...36 3.3. Industry Impact of Pharmacogenomics Regulation…………………………44 3.4. Implications for Industry…………………………………………………….46 Chapter 4 Stratified Medicine…………………………………………………………49 4.1. Genetic Variation and Implications for Medicine…………………………..49 4.2. Pharmacogenomics Applications in Practice….…………………………….50 4.3. Market Opportunities Arising from Stratified Medicine………….………...53 4.4. Cost Opportunities Arising from Stratified Medicine………….…………...57 4.5. Implications for the Biopharmaceutical Industry…………………………...61 Chapter 5 Alternative Business Model Based on Stratified Medicine………………64 5.1. The Blockbuster: An Unsustainable Model…………………………………64 5.2. Drug-Centered Business Model: The Case of Exelixis……………………..67 5.3. Patient-Centered Business Model: The Case of Roche……………………..72 5.4. Analysis of a Viable Business Model for the Stratified Medicine…..……...78 5.5. Summary for Industry Landscape…………………………………………...82 Chapter 6 Conclusions and Suggestions………………………………………………84 6.1. Concluding Remarks………………………………………………………...84 6.2. Recommendations for Future Research……………………………………..84 References……………………………………………………………………………….86 | |
dc.language.iso | en | |
dc.title | 分層醫學發展下生技製藥產業結構與商業模式之初探研究 | zh_TW |
dc.title | An Exploratory Study on the Industry Landscape and Emerging Business Models under the Development of Stratified Medicine | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳學良,邱奕嘉 | |
dc.subject.keyword | 分層醫學,製藥工業,商業模式, | zh_TW |
dc.subject.keyword | Stratified Medicine,Pharmaceutical Industry,Business Model., | en |
dc.relation.page | 89 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-02-04 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 高階公共管理組 | zh_TW |
顯示於系所單位: | 高階公共管理組 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 1.73 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。